The device has evolved from one aimed at just functional MR to a broader HF therapy. EMPOWER will provide more insights.

The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.

Dr. Vijay S. Iyer, MD, Ph.D., FACC, is a distinguished interventional cardiologist specializing in complex cardiac and structural heart interventions ...

Gregg Stone cast doubt on its reliability in trials, while David Cohen said QoL matters to patients and should be measured.

Minimally invasive heart procedures like transcatheter aortic valve replacement (TAVR) and MitraClip placement to treat mitral regurgitation can improve quality of life, and even be lifesaving, for ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

The tricuspid valve is anatomically complex. It’s often called the “forgotten valve” because of its position in the back of ...

The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive standard dataset of 16 patient-centered outcome measures for people with heart valve disease, ...

The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive standard dataset of 16 ...

February 17, 2025 - DALLAS The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...